Institution

General Hanamaki Hospital

Hanamaki, JapanWebsite

Also known as: 公益財団法人総合花巻病院 · 総合花巻病院

6running trials
1closed trial
176publications (OpenAlex)

Running trials

Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627· Phase 2· argenx· Source
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170· argenx· Source
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420· Phase 2· argenx· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Myasthenia gravis5 recruiting

Closed trials

Terminated
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
NCT04963270· Phase 3· Hoffmann-La Roche· Source

Registry name variants (5)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

General Hanamaki Hospital
Hanamaki, 025-0082
2 trials
- NCT07673627ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
  Contact: Kimiaki Utsugisawa, MD
- NCT04951622A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
General Hanamaki Hospital - Kajomachi
Hanamaki, 025-0075
2 trials
- NCT07294170ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
  Contact: Kimiaki Utsugisawa, MD
- NCT07284420ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
  Contact: Kimiaki Utsugisawa, MD
General Hanamaki Hospital
Hanamaki, Iwate, 025-0082
1 trial
- NCT04963270A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
General Hanamaki Hospital
Hanamaki-shi, 025-0075
1 trial
- NCT06558279A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
General Hanamaki Hospital - Dept of Neurology
Hanamaki-shi, Iwate 025-0082
1 trial
- NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
  Contact: Kimiaki Utsugisawa (principal investigator)

Conditions

Diseases this institution publishes on or runs trials for.

Myasthenia gravis16 works · 7 trials

Institution data: ROR 0570csa90 (CC0-1.0)Updated 14 Nov 2026

Report an error